Holen Sie sich die Stockscreener-App
34.03
1.51%
-0.52
Handel nachbörslich:
34.03
Schlusskurs vom Vortag:
$34.55
Offen:
$34.55
24-Stunden-Volumen:
923.50K
Relative Volume:
1.96
Marktkapitalisierung:
$1.69B
Einnahmen:
$499.95M
Nettoeinkommen (Verlust:
$-36.36M
KGV:
-44.19
EPS:
-0.77
Netto-Cashflow:
$24.22M
1W Leistung:
-6.69%
1M Leistung:
-2.24%
6M Leistung:
+13.36%
1J Leistung:
+1.55%
1-Tages-Spanne:
$33.00
$35.08
1-Wochen-Bereich:
$30.93
$37.28
52-Wochen-Spanne:
$28.29
$43.11
Atricure Inc Stock (ATRC) Company Profile
Firmenname
Atricure Inc
Sektor
Telefon
513-755-4100
Adresse
7555 INNOVATION WAY, MASON, OH
Vergleichen Sie ATRC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
34.03 | 1.72B | 499.95M | -36.36M | 24.22M | -0.77 |
|
ISRG
Intuitive Surgical Inc
|
544.21 | 189.40B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
177.30 | 51.22B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
ALC
Alcon Inc
|
73.88 | 36.53B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
RMD
Resmed Inc
|
248.95 | 36.04B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
WST
West Pharmaceutical Services Inc
|
279.78 | 20.29B | 2.96B | 487.70M | 344.00M | 6.6758 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Fortgesetzt | JP Morgan | Overweight |
| 2024-04-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-23 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-29 | Eingeleitet | UBS | Buy |
| 2021-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-12-18 | Bestätigt | Needham | Buy |
| 2020-11-06 | Bestätigt | Needham | Buy |
| 2020-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2020-02-06 | Eingeleitet | BTIG Research | Buy |
| 2020-01-24 | Bestätigt | Needham | Buy |
| 2019-08-13 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-04 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Stifel | Buy |
| 2018-06-18 | Bestätigt | Needham | Buy |
| 2018-04-27 | Bestätigt | Needham | Buy |
| 2018-01-16 | Bestätigt | Needham | Buy |
| 2017-11-02 | Bestätigt | Needham | Buy |
| 2017-07-28 | Bestätigt | Needham | Buy |
| 2017-05-30 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-06-30 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2015-10-28 | Bestätigt | Needham | Buy |
| 2015-10-06 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-06 | Bestätigt | Needham | Buy |
Alle ansehen
Atricure Inc Aktie (ATRC) Neueste Nachrichten
Why AtriCure Inc. stock remains undervaluedWeekly Trend Report & AI Powered Market Entry Ideas - newser.com
Is AtriCure Inc. stock near bottom after decline2025 Top Gainers & Step-by-Step Trade Execution Guides - newser.com
How rising interest rates impact AtriCure Inc. stock2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
How sustainable is AtriCure Inc. stock dividend payoutJuly 2025 Summary & Free Daily Entry Point Trade Alerts - newser.com
AtriCure, Inc. $ATRC Stake Raised by Nicholas Company Inc. - MarketBeat
What’s the recovery path for long term holders of AtriCure Inc.July 2025 Final Week & Growth-Oriented Investment Plans - newser.com
Is AtriCure Inc. stock overvalued by current metricsWeekly Investment Report & Precise Swing Trade Entry Alerts - newser.com
AtriCure Inc. stock trendline breakdown2025 Trading Volume Trends & Daily Growth Stock Investment Tips - newser.com
Why AtriCure Inc. stock is recommended by analysts2025 Trading Recap & Intraday High Probability Setup Alerts - newser.com
AtriCure (ATRC) Is Down 8.0% After Raising 2025 Guidance and Reporting Narrower LossesHas The Bull Case Changed? - simplywall.st
Does AtriCure Inc. qualify in momentum factor screeningTrade Ideas & Real-Time Chart Breakout Alerts - newser.com
Exit strategy if you’re trapped in AtriCure Inc.Bull Run & Stepwise Swing Trade Plans - newser.com
Intraday pattern recognizer results for AtriCure Inc.Weekly Profit Analysis & Stock Portfolio Risk Management - newser.com
AtriCure, Inc. (ATRC) Analyst insights, Price targets and Recommendations - Yahoo! Finance Australia
AtriCure raises 2025 revenue outlook to $532M–$534M as product launches propel double-digit growth - MSN
AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
AtriCure’s BoxX-NoAF Trial: A Step Forward in Cardiac Surgery Innovation - MSN
AtriCure’s Earnings Call Highlights Robust Growth and Innovation - The Globe and Mail
AtriCure, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:ATRC) 2025-10-31 - Seeking Alpha
AtriCure’s HEAL-IST IDE Trial: A Promising Step in Treating Inappropriate Sinus Tachycardia - MSN
AtriCure (NASDAQ:ATRC) Sees Large Volume Increase on Strong Earnings - MarketBeat
AtriCure (ATRC) Losses Worsen 12.8% Annually, Challenging Bullish Profitability Narratives - Sahm
Atricure (ATRC) Gets a Buy from Canaccord Genuity - The Globe and Mail
AtriCure (ATRC) Margin Miss Challenges Hopes for Near-Term Profitability Despite Strong Growth Forecasts - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
AtriCure Inc. stock trend forecastInsider Selling & Smart Allocation Stock Tips - newser.com
Analyzing drawdowns of AtriCure Inc. with statistical toolsMarket Performance Summary & Capital Protection Trade Alerts - newser.com
Why AtriCure Inc. stock is seen as undervaluedRate Cut & AI Optimized Trading Strategy Guides - newser.com
Canaccord Genuity raises AtriCure stock price target to $64 on strong Q3 results - Investing.com Nigeria
AtriCure stock maintains Buy rating at Needham following strong Q3 results - Investing.com Nigeria
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial - MedTech Intelligence
AtriCure stock maintains Buy rating at Needham following strong Q3 results By Investing.com - Investing.com South Africa
AtriCure stock rises as Citizens reiterates Market Outperform rating after strong Q3 - Investing.com UK
Is AtriCure Inc. stock trading near support levels2025 Top Decliners & AI Driven Stock Reports - newser.com
AtriCure, Inc. Reports Strong Q3 2025 Results - The Globe and Mail
Decoding AtriCure Inc (ATRC): A Strategic SWOT Insight - GuruFocus
AtriCure (NASDAQ:ATRC) Updates FY 2025 Earnings Guidance - MarketBeat
Canaccord Genuity Maintains AtriCure (ATRC) Buy Recommendation - Nasdaq
AtriCure (NASDAQ:ATRC) Posts Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
AtriCure Inc (ATRC) Q3 2025 Earnings Call Highlights: Strong Rev - GuruFocus
AtriCure (ATRC) Q3 2025 Earnings Call Transcript - AOL.com
AtriCure, Inc. SEC 10-Q Report - TradingView
[10-Q] AtriCure, Inc. Quarterly Earnings Report | ATRC SEC FilingForm 10-Q - Stock Titan
AtriCure (ATRC) Target Price Raised by Canaccord Genuity | ATRC Stock News - GuruFocus
AtriCure’s TRAC-AF Registry: A Closer Look at Ongoing Clinical Study - MSN
Finanzdaten der Atricure Inc-Aktie (ATRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.41%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):